1. Recurrence after cytoreductive surgery and HIPEC for pseudomyxoma peritonei: A single-center retrospective cohort study.
- Author
-
Yrjönen A, Koskenvuo L, Haapamäki C, and Lepistö A
- Subjects
- Humans, Female, Male, Middle Aged, Retrospective Studies, Aged, Adult, Combined Modality Therapy, Survival Rate, Finland, Pseudomyxoma Peritonei therapy, Pseudomyxoma Peritonei mortality, Cytoreduction Surgical Procedures, Peritoneal Neoplasms therapy, Peritoneal Neoplasms mortality, Hyperthermic Intraperitoneal Chemotherapy, Neoplasm Recurrence, Local therapy
- Abstract
Background and Aims: Pseudomyxoma peritonei (PMP) is a rare disease characterized by progressive build-up of mucinous deposits inside the abdominal cavity. The aim of this study was to investigate the effect of disease recurrence on overall survival in patients with PMP after cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC)., Methods: One-hundred thirty-two consecutive PMP patients treated with CRS + HIPEC at Helsinki University Hospital between 2008 and 2017 were included. The impact of clinicopathological and treatment-related characteristics on recurrence and overall survival was evaluated., Results: The median follow-up time in the study was 5.04 (range = 0.05-11.60) years. In 121 (91.7%) patients, the disease was classified as low grade and 11 (8.3%) had high-grade disease. In the low-grade group, 26 (21.5%) patients developed a recurrence during follow-up compared to 6 (54.5%) patients in the high-grade group. In the low-grade group, cumulative survival was 98.2%, 91.4%, and 91.4% at 3, 6, and 8 years, respectively. In the high-grade group, cumulative survival was 90.0% and 78.8% at 3 and 6 years, respectively. In patients with recurrent disease, the cumulative survival was 100%, 84.6%, and 84.6% at 3, 6, and 8 years in the low-grade category and 80.0% and 60.0% at 3 and 6 years in the high-grade category, respectively. In the low-grade group, a statistically significant correlation with recurrence but not with overall survival was identified with peritoneal cancer index (PCI), carcinoembryonic antigen (CEA), and the number of affected regions., Conclusion: The recurrence of low-grade PMP does not significantly affect overall survival of patients. Disease extent may not be a prognostic indicator after curative CRS and HIPEC in low-grade PMP., Competing Interests: Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: A.Y. has nothing to declare. L.K. declares grants from Mary and Georg Ehrnrooth’s Foundation and Cancer Foundation Finland (Syöpäsäätiö), outside the submitted work. C.H. and A.L. have nothing to declare.
- Published
- 2024
- Full Text
- View/download PDF